ASG is commercializing a silicon-based biosensor platform that enables rapid detection and measurement of proteins directly in solution. The technology delivers results in under 15 minutes, supports multiplexed testing on a single chip, and is manufactured using scalable silicon-based processes.
Protein analytics are essential to biologics development and manufacturing, yet current methods were developed decades ago. These legacy methods are accurate but slow, labor-intensive, and costly—creating bottlenecks in drug development and quality control (QC). ASG addresses these limitations by enabling faster, more scalable protein measurements aligned with modern biomanufacturing needs.
ELISA is a trusted industry standard, but typically requires 4 hours to deliver results and often measures one analyte at a time. ASG’s platform complements these methods by providing rapid, multiplexed protein measurements that enable faster decision-making earlier in development and during manufacturing readiness activities.
The platform is designed to meet sensitivity and precision requirements relevant to biomanufacturing workflows. Performance targets—such as limits of detection, precision, and sample compatibility—are defined upfront during pilot studies to ensure the data is fit-for-purpose and reproducible in real manufacturing environments.
Add a dThe biosensor is designed for protein measurements directly in solution, including sample types relevant to upstream and downstream bioprocessing. Sample compatibility is evaluated during pilot studies to ensure alignment with partner workflows and materials.escription about this item
Scalability is a core advantage of ASG’s silicon-based approach. The biosensors leverage established semiconductor manufacturing techniques, enabling consistent performance, cost efficiency, and deployment across multiple programs or manufacturing sites.
ASG engages partners through a structured pilot-to-scale adoption model. Initial pilots include clearly defined acceptance criteria—such as performance metrics and workflow fit—allowing organizations to evaluate the technology in their own environments before scaling deployment.
ASG’s platform supports faster and more robust generation of analytical data used in CMC and QC documentation. Rapid and multiplexed protein measurements can improve process understanding, comparability assessments, and the timeliness of regulatory submissions when appropriately validated and integrated into quality systems.
The platform reduces hands-on assay time and simplifies workflows, easing the burden on analytical teams. This allows skilled staff to focus on higher-value activities such as investigations, method development, and process optimization—supporting both efficiency and workforce development goals.
Modern biomanufacturing is moving faster—but protein analytics have not kept pace. ASG enables protein measurements at manufacturing speed, reducing cycle time while strengthening quality, regulatory readiness, and workforce efficiency.